Tofogliflozin decreases body fat mass and improves peripheral insulin resistance
Diabetes, Obesity and Metabolism Jan 10, 2018
Matsuba R, et al. - The researchers examined the effect of tofogliflozin, a sodium glucose transporter 2 inhibitor, on peripheral glucose uptake in patients with type 2 diabetes mellitus (T2DM) by the hyperinsulinemic-euglycemic clamp method in a single-arm, open-label study. Among T2DM patients, tofogliflozin significantly improved insulin sensitivity and peripheral glucose uptake. These improvements were significantly associated with a reduction of body fat mass.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries